Altering the Course of Degenerative Diseases


Altering the Course of Degenerative Diseases


Altering the Course of Degenerative Diseases

CTAD 2021: Top-line Results from the GAIN Trial

A Phase 2/3 Study of Atuzaginstat in Mild to Moderate Alzheimer’s Disease

Cortexyme presented additional data from our Phase 2/3 GAIN Trial at CTAD 2021, expanding on the previously reported topline results that demonstrated the relationship between the reduction of P. gingivalis infection and the slowing of cognitive decline in Alzheimer’s disease with atuzaginstat treatment in a prespecified population of patients based on diagnosis of infection.

GAIN Trial top-line results.

Cortexyme reports GAIN Trial data demonstrated relationship between reduction of P. gingivalis infection and slowing of Alzheimer’s disease progression. Learn more about our GAIN Trial top-line results and next steps to advance this potentially breakthrough treatment for the benefit of patients and their families.

A unique and powerful approach.

Cortexyme is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients that causes neurodegeneration and other pathology in animal models. Additional programs are progressing in preclinical development.




Look Inside

Targeting the pathogenic cause of neurodegeneration

Cortexyme in the news

January 26, 2022 in News

Cortexyme Announces Clinical Hold on Atuzaginstat’s Investigational New Drug Application

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cortexyme, Inc. (Nasdaq: CRTX), a clinical-stage biopharmaceutical company focused on Alzheimer’s and other degenerative diseases, today…
Read More
November 23, 2021 in Events, News

Cortexyme to Present at 4th Annual Evercore ISI HealthCONx Conference on November 30th

SOUTH SAN FRANCISCO, Calif. – November 23, 2021 – Cortexyme, Inc. (Nasdaq: CRTX) announced that Casey Lynch, chief executive officer,…
Read More
November 11, 2021 in Events, News

Cortexyme’s Atuzaginstat Slowed Cognitive Decline in Participants with Alzheimer’s Disease and P. Gingivalis Infection in Phase 2/3 GAIN Trial: Additional Top-line Data Presented at CTAD 2021

Evidence supports P. gingivalis as a driver of Alzheimer’s in easily identified patient population Successful identification of target population and…
Read More

Do You or Someone You Love Have Alzheimer’s Disease?